Evaluation of risk factors in patients with vulvovaginal candidiasis and the value of chromID Candida agar versus CHROMagar Candida for recovery and presumptive identification of vaginal yeast species
- PMID:20608776
- DOI: 10.3109/13693786.2010.497972
Evaluation of risk factors in patients with vulvovaginal candidiasis and the value of chromID Candida agar versus CHROMagar Candida for recovery and presumptive identification of vaginal yeast species
Abstract
Vulvovaginal candidiasis (VVC), particularly the recurrent form, remains an intractable problem for clinicians, microbiologists, and patients. It is essential to confirm the clinical diagnosis by mycological methods and avoid empirical therapy. The recovery of yeast in fungal culture, such as on Sabouraud dextrose agar, remains the gold standard for diagnosis. In this investigation, we examined 474 participants, including 122 (25.7%) with acute VVC cases, 249 (52.5%) who had recurrent VVC (RVVC) cases, and 103 (21.7%) healthy controls. We also administered a questionnaire to obtain information on patient lifestyle and medical, gynecological, and sexual history. In addition, we compared the performance of chromID Candida agar (CAN2) to CHROMagar Candida (CAC) and Sabouraud dextrose agar with gentamicin and chloramphenicol (SGC2). The yeasts were identified by conventional methods including the germ tube test, microscopic morphology on cornmeal-Tween 80 agar, and the commercial API 20C AUX system. We detected yeasts in 60 of 122 (49.2%) patients with acute VVC cases, 110 of 249 (44.2%) with RVVC cases, and in 35 of 103 (34%) healthy controls (P = 0.07). A total of 205 samples were found to be positive for fungi (43.2%), of which 176 (85.9%) were monofungal, and 29 (14.1%) were polyfungal. In addition, 198 of these samples (96.6%) were positive on CAN2, 195 (95.1%) on CAC, 189 (92.2%) on SGC2, and 183 (89.3%) samples on all three (P = 0.17). The 234 yeast isolates recovered were C. albicans (n = 118), C. glabrata (n = 82), C. kefyr (n = 11), C. krusei (n = 9), C. lipolytica (n = 3), C. colliculosa (n = 2), C. parapsilosis (n = 2), C. pelliculosa (n = 2), C. tropicalis (n = 2), and other species of Candida (n = 3). Of the 29 polyfungal populations, 28 (96.6%) were detected in CAN2, 25 in (86.2%) CAC, and 25 (86.2%) on both (P = 0.35). Notably, we detected the high predominance of C. albicans+C. glabrata (86.2%) in polyfungal populations. Briefly, the detection of C. albicans after 24 h of incubation was easier on CAN2 (64.4%) than on CAC (25.4%). This study showed that CAN2 is a rapid and reliable medium for immediate identification of C. albicans and for detecting polyfungal populations in vaginal specimens. We observed that the use of antibiotics, intrauterine devices, as well as, perineal laceration, short anovaginal distance (< 3 cm), and genital epilation in common areas are predisposing factors for RVVC (P < 0.001). In addition, we detected that the use of menstrual pad, using an (IUD), and having a history of childbirth increased the risk of both acute and recurrent VVC (P < 0.01), whereas the use of a daily pad and walking daily significantly decreased the risk of both acute and recurrent VVC (P < 0.01).
Similar articles
- Performance of Chromogenic Candida agar and CHROMagar Candida in recovery and presumptive identification of monofungal and polyfungal vaginal isolates.Ozcan K, Ilkit M, Ates A, Turac-Bicer A, Demirhindi H.Ozcan K, et al.Med Mycol. 2010 Feb;48(1):29-34. doi: 10.3109/13693780802713224.Med Mycol. 2010.PMID:19191167
- An evaluation of risk factors in pregnant women with Candida vaginitis and the diagnostic value of simultaneous vaginal and rectal sampling.Guzel AB, Ilkit M, Burgut R, Urunsak IF, Ozgunen FT.Guzel AB, et al.Mycopathologia. 2011 Jul;172(1):25-36. doi: 10.1007/s11046-011-9392-z. Epub 2011 Feb 4.Mycopathologia. 2011.PMID:21293929
- Can the diagnosis of recurrent vulvovaginal candidosis be improved by use of vaginal lavage samples and cultures on chromogenic agar?Novikova N, Rodrigues A, Mårdh PA.Novikova N, et al.Infect Dis Obstet Gynecol. 2002;10(2):89-92. doi: 10.1155/S1064744902000078.Infect Dis Obstet Gynecol. 2002.PMID:12530485Free PMC article.
- The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: a mycological perspective.Ilkit M, Guzel AB.Ilkit M, et al.Crit Rev Microbiol. 2011 Aug;37(3):250-61. doi: 10.3109/1040841X.2011.576332. Epub 2011 May 20.Crit Rev Microbiol. 2011.PMID:21599498Review.
- Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors.Gonçalves B, Ferreira C, Alves CT, Henriques M, Azeredo J, Silva S.Gonçalves B, et al.Crit Rev Microbiol. 2016 Nov;42(6):905-27. doi: 10.3109/1040841X.2015.1091805. Epub 2015 Dec 21.Crit Rev Microbiol. 2016.PMID:26690853Review.
Cited by
- The Role of PCR in the Diagnosis of Candida Vulvovaginitis-a New Gold Standard?Sobel JD, Akins RA.Sobel JD, et al.Curr Infect Dis Rep. 2015 Jun;17(6):488. doi: 10.1007/s11908-015-0488-3.Curr Infect Dis Rep. 2015.PMID:26003471
- Hosting infection: experimental models to assay Candida virulence.Maccallum DM.Maccallum DM.Int J Microbiol. 2012;2012:363764. doi: 10.1155/2012/363764. Epub 2011 Dec 22.Int J Microbiol. 2012.PMID:22235206Free PMC article.
- Persistent, Asymptomatic Colonization withCandida is Associated with Elevated Frequencies of Highly Activated Cervical Th17-Like Cells and Related Cytokines in the Reproductive Tract of South African Adolescents.Happel AU, Gasper M, Balle C, Konstantinus I, Gamieldien H, Dabee S, Gill K, Bekker LG, Passmore JS, Jaspan HB.Happel AU, et al.Microbiol Spectr. 2022 Apr 27;10(2):e0162621. doi: 10.1128/spectrum.01626-21. Epub 2022 Mar 29.Microbiol Spectr. 2022.PMID:35348351Free PMC article.Clinical Trial.
- Clinical and Laboratory Features of Six Cases of Candida and Dermatophyte Folliculitis and a Review of Published Studies.Durdu M, Güran M, Kandemir H, Ilkit M, Seyedmousavi S.Durdu M, et al.Mycopathologia. 2016 Feb;181(1-2):97-105. doi: 10.1007/s11046-015-9939-5. Epub 2015 Sep 4.Mycopathologia. 2016.PMID:26337525
- Trichomonas, Candida, and gardnerella in cervical smears of Iranian women for cancer screening.Kalantari N, Ghaffari S, Bayani M.Kalantari N, et al.N Am J Med Sci. 2014 Jan;6(1):25-9. doi: 10.4103/1947-2714.125861.N Am J Med Sci. 2014.PMID:24678473Free PMC article.
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources